LLY vs. RDY: Eli Lilly vs. Dr. Reddy's Laboratories Stock Comparison

November 11, 2026

How do Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Eli Lilly (LLY) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY)
Profile Item	LLY	RDY
Name	Eli Lilly and Company	Dr. Reddy's Laboratories Ltd. ADR
Country/Region	United States	India
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Pharmaceuticals
GICS Sub-Industry	Pharmaceuticals	Pharmaceuticals
Market Capitalization	1,206.07 billion USD	12.43 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	June 1, 1972	April 11, 2001
Security Type	Common Stock	ADR

Price Performance

Cumulative Growth

LLY

RDY

GSPC

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY)
Metric	LLY	RDY
Total Return (1Y)	52.36%	12.49%
Total Return (3Y, Annualized)	34.18%	5.76%
Total Return (5Y, Annualized)	41.08%	4.06%

Risk Profile

Drawdown History

LLY

RDY

GSPC

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY)
Metric	LLY	RDY
Volatility (1Y, Annualized)	35.34%	27.06%
Beta (5Y)	0.40	0.30
Max Drawdown (5Y)	-34.48%	-32.01%
Avg. Volume (3M)	2.52M	2.89M

Risk-Adjusted Performance

Risk-Return Positioning

LLY and RDY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY)
Metric	LLY	RDY
Sharpe Ratio (1Y)	1.36	0.30
Sortino Ratio (1Y)	2.29	0.43

Profitability

ROE (TTM)

Both Eli Lilly (LLY) at 86.02% and Dr. Reddy's Laboratories (RDY) at 7.34% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max: 109.18%
LLY: 86.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.34%

Max: 109.18%
RDY: 7.34%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Eli Lilly (LLY) at 31.90% keeps the most of each sales dollar — above its industry’s net margin range — and Dr. Reddy's Laboratories (RDY) at 8.49% also retains a top-quartile share.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY: 31.90%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.49%

Max: 18.05%
RDY: 8.49%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Eli Lilly (LLY) at 53.66% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max: 83.12%
LLY: 53.66%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.73%

Max: 83.12%
Q3: 14.77%
RDY: 14.73%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY)
Metric	LLY	RDY
ROE (TTM)	86.02%	7.34%
ROA (TTM)	21.06%	3.37%
Net Margin (TTM)	31.90%	8.49%
Operating Margin (TTM)	53.66%	14.73%
Gross Margin (TTM)	83.63%	49.49%

Growth

Revenue Growth

Both Eli Lilly (LLY) at 44.70% and Dr. Reddy's Laboratories (RDY) at 3.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Dr. Reddy's Laboratories (RDY) at -24.14% is closer to the peer norm — faster per-share earnings growth for LLY.

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY)
Metric	LLY	RDY
Revenue Growth (YoY)	44.70%	3.19%
Revenue Growth (3Y CAGR)	31.69%	10.96%
EPS Growth (YoY)	95.99%	-24.14%
EPS Growth (3Y CAGR)	51.71%	-1.72%

Financial Strength

Current Ratio (MRQ)

Both Eli Lilly (LLY) at 1.39 and Dr. Reddy's Laboratories (RDY) at 1.93 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
LLY: 1.39
Min: 0.10

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.93

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
RDY: 1.93
Min: 0.10

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Dr. Reddy's Laboratories (RDY) at 0.19 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.23 uses more debt funding than most peers.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max: 1.42
LLY: 1.23
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max: 1.42
Q3: 0.65
RDY: 0.19
Median: 0.15
Q1: 0.02
Min: 0.00

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY)
Metric	LLY	RDY
Current Ratio (MRQ)	1.39	1.93
Debt / Equity (MRQ)	1.23	0.19
Net Debt / EBITDA	0.96	-0.08

Dividends

Dividend Yield (TTM)

Both Eli Lilly (LLY) at 0.49% and Dr. Reddy's Laboratories (RDY) at 55.06% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY: 0.49%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

55.06%

RDY: 55.06%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Eli Lilly (LLY) at 21.71% and Dr. Reddy's Laboratories (RDY) at 22.72% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY: 21.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.72%

RDY: 22.72%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY)
Metric	LLY	RDY
Dividend Yield (TTM)	0.49%	55.06%
Dividend Payout Ratio (TTM)	21.71%	22.72%

Valuation

P/E Ratio (TTM)

Dr. Reddy's Laboratories (RDY) at 41.42 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max: 85.34
LLY: 43.95
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.42

Max: 85.34
Q3: 43.46
RDY: 41.42
Median: 26.69
Q1: 13.30
Min: 0.07

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Eli Lilly (LLY) at 13.95 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max: 58.18
Q3: 25.77
LLY: 13.95
Median: 7.30
Q1: 3.01
Min: 0.01

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
RDY: 0.04
Min: 0.01

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both Eli Lilly (LLY) at 29.96 and Dr. Reddy's Laboratories (RDY) at 18.16 look expensive — each P/B ratio sits above its industry’s benchmark range.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY: 29.96
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.16

RDY: 18.16
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Eli Lilly (LLY) vs. Dr. Reddy's Laboratories (RDY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Eli Lilly (LLY) and Dr. Reddy's Laboratories (RDY)
Metric	LLY	RDY
P/E Ratio (TTM)	43.95	41.42
P/S Ratio (TTM)	13.95	0.04
P/B Ratio (MRQ)	29.96	18.16
Free Cash Flow Yield (TTM)	0.77%	-53.03%